Your Position: Home > Journal List > China Medicine > Paper

Clinical study of irinotecan combined with suitable-symptom nutritional supporting treatment for advanced metastatic colorectal cancer

( views:88, downloads:0 )
Author:
GENG Shu-mei(Department of Medical Oncology, First Center Hospital of Baoding , Hebei Province, Baoding 071000, China)
Journal Title:
China Medicine
Issue:
Volume 07, Issue 10, 2012
DOI:
10.3760/cma.j.issn.1673-4777.2012.10.025
Key Word:
Advanced metastatic colorectal cancer; Irinotecan; Suitable-symptom nutritional support

Abstract: Objective To evaluate the clinical efficacy and the toxicity of irinotecan combined with suitable-symptom nutritional supporting treatment for patients with advanced metastatic colorectal cancer who were intolerant of chemotherapy.Methods Twenty-four patients with tumor node metastases(TNM)stage Ⅳ advanced metastatic colorectal cancer were enrolled,and their Karnofsky performance status(KPS)score was 40-60.The observation group had 13 cases and the control group was 11 cases.The observation group was treated by irinotecan and suitable-symptom nutritional support; the control group was treated by suitable-symptom nutritional support.Results Tumor response rate of patients was 15.4%(2/13)in the observation group; the disease control rate was 53.8%(7/13).Survival rate of 1-year in the observation group was higher than that in the control group [53.8(7/13)vs 27.3(3/11),P < 0.05]; KPS increasing rate was higher than that of the control group [53.8(7/13)vs 27.3(3/11),P < 0.05].Adverse chemotherapy reaction was tolerable.Conclusions Disease control rate and 1-year survival rate in the observation group are significantly higher than those in the control group in advanced metastatic colorectal cancer.It can improve life quality.Patient tolerance and compliance are satisfactory.

  • [1]万德森,陈功.结直肠癌的流行病学及其危险因素研究近况.实用癌症杂志,2000,15(2):109-111.
  • [2]Cats A.New developments in systemic chemotherapy in advanced colorectal cancer.Scand J Gastroenterol Suppl,2003,(239):78-86.
  • [3]陈智伟,廖美琳,陈玉蓉,等.WHO标准和RECIST标准评价肺癌化疗疗效的比较.循证医学,2004,4(2):83-84.
  • [4]徐丽叶,宋晨,方丽萍,等.甲羟孕酮对晚期乳腺癌化疗患者生活质量影响.吉林医学,2011,32(18):16-17.
  • [5]Helsing M,Bergman B,Thaning L,et al.Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only.A muhicentre randomised phase Ⅲ trial.Joint Lung Cancer Study Group.Eur J Cancer,1998,34(7):1036-1044.
  • [6]Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer:evidence in terms of response rate.Advanced Colorectal Cancer Meta-Analysis Project.J Clin Oncol,1992,10(6):896-903.
  • [7]吴敏,王利娟,张红巧.卡培他滨单药治疗高龄转移性结直肠癌疗效观察.中华肿瘤防治杂志,2006,8(20):85.
  • [8]Maughan TS,James RD,Kerr DJ,et al.Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer:a multicentre randomised trial.Lancet,2003,361(9356):457-464.
  • [9]Cunningham D,Pyrhonen S,James RD,et al.Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.Lancet,1998,352(9138):1413-1418.
  • [10]彭云武.CPT-11临床应用进展.现代肿瘤医学,2009,17(8):1594-1598.
  • [11]苏洋,张俊,朱正纲.UGT1 A1基因多态性与伊立替康临床疗效及安全性的关系.临床肿瘤学杂志,2011,16(4):362-366.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn